These reports suggest that prevention of CD4+ T cell depletion, modulation of the hepatic immunological pattern, and inhibition of chronic inflammation could prevent the progression of NAFLD to HCC [5,7]. The gene discussed is CD4; the disease is metabolic dysfunction-associated steatotic liver disease.